Global, regional, and national burden of gout among older adults (≥65) from 1990 to 2021 and projections for 2050

Background: Gout, a common and treatable type of inflammatory arthritis, is caused by the buildup of monosodium urate crystals in the synovial fluid and other tissues. This study uses epidemiological modeling to analyze the global impact of gout among older adults (≥65) from 1990 to 2021, with projections extending to 2050, using the most recent data from the Global Burden of Disease (GBD) 2021.

Method: Data from the GBD 2021 database were used to evaluate the global burden of gout in adults aged 65 and older from 1990 to 2021. The analysis considered factors such as age group (65+), gender, year (1990–2021), geographic classification [204 countries/regions, five socio-demographic index (SDI) regions, 21 GBD regions], and the SDI. Metrics assessed included incidence, prevalence, and disability-adjusted life years (DALYs), with their 95% uncertainty intervals (UI). All metrics were age-standardized using the GBD global standard population.

Results: In 2021, the global age-standardized incidence rate of gout among older adults was 432.70 (95% UI: 263.28, 677.27) per 100,000 population. The age-standardized prevalence rate was 3,110.84 (95% UI: 2,092.83, 4,419.20) per 100,000, and the age-standardized DALYs were 90.90 (95% UI: 54.95, 139.13) per 100,000 person-years. There was an increasing trend in the incidence rate, prevalence, and DALYs as age increased among those 65 and older. The disease burden among older males was nearly twice that of females. Projections for 2050 show that the age-standardized incidence rate, prevalence rate, and DALYs are expected to increase to 524.99, 3,628.85, and 105.36 per 100,000 population, respectively. Metabolic risks have become the primary risk factor for gout.

Discussion: Due to global population aging, our predictive model estimates that by 2050, the number of older adults with gout will increase by 8.5 million. The rise is particularly pronounced in high-SDI and high-income regions, highlighting the need for stronger prevention and management strategies in these areas. Early intervention in metabolic risk factors and improved early diagnosis and treatment are essential for effective gout management.

1 Introduction

Gout is a chronic inflammatory arthropathy driven by dysregulation of uric acid metabolism, characterized by persistent hyperuricemia (serum uric acid concentration >6.8 mg/dl) and an inflammatory response secondary to monosodium urate (MSU) crystal deposition (1). Hyperuricemia typically results from abnormalities in purine metabolism, impaired renal uric acid excretion, and dysregulated enzymatic activities, including overactivation of phosphoribosyl pyrophosphate synthetase, deficiency of hypoxanthine-guanine phosphoribosyltransferase, and increased catalytic activity of xanthine oxidase (2). Additionally, dysfunction of urate transporters in renal proximal tubules further compromises uric acid clearance (3). When serum uric acid levels surpass the solubility threshold, MSU crystals precipitate preferentially within the low-pH, low-temperature microenvironment of the joints, initiating a cascade of innate immune responses. Macrophage phagocytosis of MSU crystals triggers assembly of the NLRP3 inflammasome, culminating in caspase-1 activation, IL-1β maturation and release, and subsequent massive recruitment of neutrophils, leading to acute inflammation and tissue injury (4). During the chronic phase, persistent crystal deposition promotes tophus formation, characterized by imbalanced macrophage (M1/M2) polarization and fibrotic encapsulation, ultimately resulting in cartilage degradation, bone erosion, and irreversible joint deformities.

Beyond acute gouty arthritis and intense pain episodes, gout exerts systemic effects through sustained inflammation, contributing to multi-organ damage and posing a significant burden on patient health. With the accelerating global aging process, the incidence of gout among older adult is increasing annually. The global prevalence of gout is estimated to be 1%−6.8%, with rates ranging from 1 to 4% in Europe and 3.9% in the United States (5–7). According to the 2008 U.S. National Health and Nutrition Examination Survey, ~4.7 million older adult individuals in the country have gout (8). Moreover, a cohort study indicated that about 31.9% of gout patients were diagnosed at the age of 65 or older (9).

Studies have shown that the risk of developing gout increases significantly with age and is particularly prevalent in aging populations (10). This disease not only severely impacts individual physical and mental health and increases economic burdens but also poses significant challenges to global healthcare systems. According to the 2020 Global Burden of Disease (GBD) study, the global years lived with disability (YLDs) due to gout increased from 122,000 in 1990 to 239,000 in 2020 (11).

Currently, most studies on gout utilize data collected prior to 2019, focusing primarily on general populations or disease burden analyses limited to specific regions (9–16). However, there is a lack of sufficient evidence on the prevalence of gout and its global epidemiological trends specifically in older adult population. Therefore, a comprehensive assessment of the current global gout burden in older adult, along with medium- and long-term trend projections, is urgently needed to inform effective strategies.

This study utilized the latest 2021 GBD data and applied epidemiological models to systematically analyze the global burden of gout in older adult from 1990 to 2021 and projected trends for 2050. The study aims to uncover differences in the gout burden among older adult across gender, age groups, and regional distributions, providing scientific evidence for targeted interventions and resource allocation strategies.

2 Methods

2.1 Data sources

The GBD 2021 database (https://vizhub.healthdata.org/gbd-results/), which offers disease burden data for 371 diseases and 88 risk variables across 204 nations and territories worldwide, served as the sole source of statistics for this investigation. The database collects data and evaluates metrics using established procedures (38). The study focused on extracting gout-related data for individuals aged 65 years and older from 1990 to 2021 to assess its prevalence trends and disease burden.

The extracted data included the following dimensions: demographic characteristics (age group 65+, gender, years 1990–2021), geographic classifications (204 countries/territories globally, including WHO member states, five SDI regions, and 21 GBD regions), and the socio-demographic index (SDI), which measures socioeconomic context through indicators such as total fertility rate for individuals under 25, mean years of schooling for individuals aged 15 and above, and per capita lag-distributed income (39). Five SDI levels were applied to the 204 countries and territories: low, low-middle, middle, high-middle, and high. Within the 21 GBD regions, regional classifications were made according to geographic proximity and epidemiological similarity (40).

2.2 Analytical metrics

This study used measures including incidence, prevalence, and Disability-Adjusted Life Years (DALYs) and their associated 95% uncertainty intervals (UI) to analyze the disease burden of gout in people 65 and older. The age distribution of the GBD global standard population was used to compute age-standardized rates for incidence, prevalence, and DALYs.

2.3 Statistical methods

Statistical analyses of the global gout disease burden in older adults from 1990 to 2021 were conducted using Excel 2021 and R (version 4.3.3). After cleaning and organizing the collected data, statistical analyses and visualizations were performed using R packages such as dplyr, officer, and ggplot2. Statistical significance was established at a level of P < 0.05.

2.3.1 Age-group analysis

Permission must be obtained for use of copyrighted material from other sources (including the web). Please note that it is compulsory to follow figure instructions.

The study population was split into seven age groups: 65–69, 70–74, 75–79, 80–84, 85–89, 90–94, and 95+ years old, in accordance with the age-grouping guidelines of GBD 2021. The dynamics of gout disease burden variations across these age groups and genders were investigated.

2.3.2 Trend analysis

Percentage change (EAPC): R software was used to calculate and visualize the percentage change in gout disease burden across age groups, genders, regions, and countries from 1990 to 2021. The Estimated Annual Percentage Change (EAPC) was used to quantify trends in age-standardized rates. An EAPC with a 95% confidence interval lower bound >0 indicates an upward trend in age-standardized rates, whereas a lower bound ≤ 0 indicates a downward trend (41).

Joinpoint Regression Model: The Joinpoint regression model, which determines the Average Annual Percent Change (AAPC) and Annual Percent Change (APC) for particular periods, was used to study time patterns from 1990 to 2021. If the 95% confidence interval includes 0, the trend is considered stable. An AAPC or APC significantly > or < 0 indicates an upward or downward trend, respectively, for the relevant metrics (42). Model fitting and AAPC/APC calculations were conducted using Joinpoint software (version 4.9.0.0) with visualizations produced in R.

2.3.3 Correlation analysis

The association between age-standardized gout rates and the SDI was assessed using Pearson correlation analysis. Furthermore, the percentages of gout attributable to kidney disease, metabolic hazards, and high body mass index were examined.

2.4 Decomposition and forecast analysis

Decomposition analysis: while controlling for other variables, decomposition techniques were used to measure the separate contributions of aging, population expansion, and epidemiological changes to the burden of gout (43).

Age-period-cohort analysis: the dynamic impact of age, period, and cohort characteristics on gout were evaluated using the Age-Period-Cohort (APC) model. To examine the impact of variables on gout incidence and mortality risk, the APC model, which is based on a Poisson distribution, breaks them down into three dimensions: age, period, and cohort (44).

Bayesian age-period-cohort model (BAPC): building on the APC model, the BAPC model incorporates Bayesian Markov Chain Monte Carlo algorithms to address parameter estimation challenges caused by the linear relationship among the three factors. This model was used to predict the burden of gout from 2022 to 2050 (45).

3 Results

3.1 Global burden of gout in older adults

In 2021, the age-standardized incidence rate of gout among older adults was 432.70 (95% UI: 263.28, 677.27) per 100,000 population, the age-standardized prevalence rate was 3,110.84 (95% UI: 2,092.83, 4,419.20) per 100,000 population, and the age-standardized DALYs were 90.90 (95% UI: 54.95, 139.13) per 100,000 person-years. This indicates that 3,318,171.28 (95% UI: 2,018,433.81, 5,197,653.84) new gout cases occurred in 2021, including 2,207,869.69 (95% UI: 1,339,816.28, 3,459,256.11) males and 1,110,301.60 (95% UI: 678,416.45, 1,741,293.44) females. The total number of gout cases in 2021 was 23,730,400.86 (95% UI: 15,953,641.14, 33,717,972.23), of which 16,184,603.23 (95% UI: 10,879,440.36, 22,961,992.04) were males and 7,545,797.63 (95% UI: 5,014,123.94, 10,792,915.18) were females. Gout resulted in 695,181.04 (95% UI: 419,889.66, 1,063,310.19) DALYs in 2021, including 476,926.92 (95% UI: 288,335.10, 728,546.18) DALYs among males and 218,254.11 (95% UI: 130,848.00, 334,754.44) DALYs among females. From 1990 to 2021, all disease burden metrics for gout in older adults showed positive EAPC values, indicating a general increasing trend in the global disease burden of gout in this population (see Table 1).

Table 1

Table 1. Age-standardized gout burden findings for 21 GBD regions, five SDI regions, and the general population worldwide.

3.2 Regional burden of gout in older adults

Among the five SDI regions, the High SDI region had the highest age-standardized incidence rate [471.11 (95% UI: 281.95, 750.64)], age-standardized prevalence rate [4,528.67 (95% UI: 3,133.57, 6,270.79)], and age-standardized DALYs [131.85 (95% UI: 82.21,200.16)]. Conversely, the low-middle SDI region had the lowest age-standardized incidence rate [348.43 (95% UI: 213.59, 540.01)], age-standardized prevalence rate [2,026.56 (95% UI: 1,316.54, 2,937.43)], and age-standardized DALYs [58.66 (95% UI: 34.40, 92.13)]. From a temporal perspective, all gout burden metrics increased across SDI regions. The High SDI region showed the most significant increases in incidence rate [EAPC = 0.97 (95% UI: 0.24, 1.71)] and prevalence rate [EAPC = 1.61 (95% UI: 0.69, 2.55)], while the Low SDI region exhibited the most significant increase in DALYs [EAPC = 1.58 (95% UI: 0.64, 2.52); see Table 1].

Among the 21 GBD regions, Australasia had the highest age-standardized incidence rate (693.52, 95% UI: 406.80, 1,120.74), age-standardized prevalence rate (7,641.08, 95% UI: 5,170.47, 10,784.04), and age-standardized DALYs (224.58, 95% UI: 134.72, 349.07) in 2021. In contrast, Central Latin America had the lowest age-standardized incidence rate (121.36, 95% UI: 73.38, 189.56), age-standardized prevalence rate (673.75, 95% UI: 432.88, 991.68), and age-standardized DALYs (20.08, 95% UI: 11.50, 31.59). From a temporal perspective, the disease burden increased across all GBD regions. High-income North America exhibited the most severe increases, with the incidence rate (EAPC = 1.79, 95% UI: 1.13, 2.45), prevalence rate (EAPC = 2.99, 95% UI: 2.08, 3.91), and DALYs (EAPC = 2.92, 95% UI: 2.01, 3.85) showing the greatest growth (see Table 1).

3.3 National and regional burden of gout in older adults

With an age-standardized incidence rate of 771.87 (95% UI: 446.87, 1,250.88) per 100,000 population, New Zealand had the highest rate of gout among older persons in 2021. Australia had the highest age-standardized DALYs (224.77, 95% UI: 134.77, 347.77) per 100,000 person-years and the highest age-standardized prevalence rate (7,648.30, 95% UI: 5,202.84, 10,791.44) per 100,000 population. Guatemala, on the other hand, had the lowest DALYs (17.36, 95% UI: 8.51, 29.81), prevalence rate (584.64, 95% UI: 373.13, 852.27), and age-standardized incidence rate (108.18, 95% UI: 65.44, 170.21; see Figures 1A–C). The prevalence of gout illness declined in Nigeria, the Democratic Republic of the Congo, and Somalia, according to longitudinal trend research. Furthermore, there were declining trends in Zimbabwe's age-standardized DALYs and the Netherlands' age-standardized incidence rate. However, it is noteworthy that the decreasing trends in these countries were not significant, as the 95% confidence intervals (CIs) of the EAPCs included 0. In contrast, the disease burden of gout in older adults increased in all other countries and regions (see Figures 1D–F). Among these, the United States of America exhibited the most pronounced upward trends in the age-standardized incidence rate (EAPC = 1.95, 95% UI: 1.29, 2.62), prevalence rate (EAPC = 3.27, 95% UI: 2.35, 4.20), and DALYs (EAPC = 3.20, 95% UI: 2.27, 4.13). Detailed disease burden data for 204 countries and regions are provided in Supplementary material 1.

Figure 1

Figure 1. The burden of gout in 204 countries and regions globally in 2021. (A) Age-standardized incidence rate; (B) age-standardized prevalence rate; (C) age-standardized DALYs; (D) EAPC for incidence rate; (E) EAPC for prevalence rate; (F) EAPC for DALYs.

3.4 Age-sex-time association analysis of gout in older adults

Age-sex association analysis revealed that, in 2021, the incidence rate, prevalence rate, and DALYs of gout increased with age among individuals aged 65 and older. However, this increase was not statistically significant. Additionally, the disease burden among older males was nearly twice as high as that among females (see Figures 2A–C).

Figure 2

Figure 2. Trends in the age- and sex-specific burden of gout and Joinpoint regression analysis results. (A) Incidence; (B) prevalence; (C) DALYs; (D) joinpoint analysis of incidence; (E) joinpoint analysis of prevalence; (F) joinpoint analysis of DALYs.

Age-time association analysis demonstrated that, globally, the age-standardized incidence rate, prevalence rate, and DALYs of gout across different age groups remained relatively stable from 1990 to 2021, showing no significant changes over time. However, the disease burden of gout increased with age, with older individuals bearing a higher burden (see Supplementary Figures 1–3).

Sex-time association analysis indicated that, globally, the age-standardized incidence rate, prevalence rate, and DALYs of gout among older adults remained relatively stable for both males and females from 1990 to 2021, without significant changes over time. Notably, the disease burden among males was approximately twice that of females (see Supplementary Figures 4–6).

3.5 Trends in the burden of gout in older adults

Joinpoint regression analysis revealed an overall increasing trend in the incidence, prevalence, and DALYs of gout among older adults globally from 1990 to 2021. Specifically, the AAPC for incidence was 2.575 (95% CI: 2.528, 2.621), for prevalence was 22.545 (95% CI: 21.740, 23.350), and for DALYs was 0.654 (95% CI: 0.630, 0.678). Significant changes in these three disease burden metrics were observed in the years 1994, 2001 (2000 for incidence), and 2010 (see Figures 2D–F). Since 2010, the upward trend in gout burden has slightly slowed but remains significantly increasing. The slope changes for each curve segment are detailed in Supplementary material 2.

3.6 Association between gout burden and SDI in older adults

Globally and across the 21 GBD regions, the relationship between SDI and the age-standardized incidence rate, prevalence rate, and DALYs of gout displayed a non-linear trend. Specifically, as SDI increased, the burden of gout initially decreased slowly, reaching its lowest point around an SDI value of 0.55. Beyond this point, the burden of gout began to increase slowly with higher SDI values. Among the 21 GBD regions, Australasia experienced the fastest growth in disease burden (see Figures 3A–C). Across 204 countries, there was no significant correlation between gout incidence and SDI (p = 1.508e-01). However, gout prevalence (p = 9.542e-06) and DALYs (p = 5.197e-06) increased significantly with higher SDI values. Additionally, the EAPC for prevalence and DALYs also increased with SDI, indicating that in higher SDI countries, the burden of gout is becoming more severe (see Figures 3D–I).

Figure 3

Figure 3. SDI analysis results. (A) Incidence in 21 regions; (B) prevalence in 21 regions; (C) DALYs in 21 regions; (D) incidence in 204 countries; (E) prevalence in 204 countries; (F) DALYs in 204 countries; (G) EAPC of incidence; (H) EAPC of prevalence; (I) EAPC of DALYs.

3.7 Results of age-period-cohort analysis of gout burden in older adults

The age-period-cohort analysis for the incidence, prevalence, and DALYs of gout in older adults demonstrated similar trends. The age effect analysis revealed a significant upward trend in gout disease burden with increasing age (see Figures 4A–C). The period effect analysis showed a gradual increase in the burden of gout over time from 1990 to 2021 (see Figures 4D–F). The cohort effect analysis indicated a significantly higher gout burden among later-born cohorts compared to earlier-born cohorts (see Figures 4G–I).

Figure 4

Figure 4. Age-period-cohort analysis results. (A) Age effect for incidence; (B) age effect for prevalence; (C) age effect for DALYs; (D) period effect for incidence; (E) period effect for prevalence; (F) period effect for DALYs; (G) cohort effect for incidence; (H) cohort effect for prevalence; (I) Cohort effect for DALYs.

3.8 Results of decomposition analysis of gout burden in older adults

Consistent trends were found by the decomposition analysis in the contributions of epidemiological changes, aging, and population increase to the worldwide gout burden, as well as in the five SDI areas and the 21 GBD regions. In particular, aging significantly reduced the burden of gout in High SDI and High-Middle SDI regions, as well as in Western Europe, High-Income North America, and Eastern Europe. However, in other regions, the burden of gout increased due to the combined effects of population growth, aging, and epidemiological changes. The primary cause of the increase in the burden of gout among these was population growth (see Figure 5).

Figure 5

Figure 5. Decomposition analysis results. (A) Incidence globally and in five SDI regions; (B) prevalence globally and in five SDI regions; (C) DALYs globally and in five SDI regions; (D) incidence in 21 GBD regions; (E) prevalence in 21 GBD regions; (F) DALYs in 21 GBD regions.

3.9 Results of predictive analysis of gout burden in older adults

Predictive analysis indicates that the global burden of gout among older adults will continue to rise from 2022 to 2050 (see Figure 6). By 2050, the age-standardized incidence rate, prevalence rate, and DALYs of gout in older adults are projected to increase to 524.99 (95% CI: 311.84, 738.13) per 100,000 population, 3,628.85 (95% CI: 2,159.85, 5,097.85) per 100,000 population, and 105.36 (95% CI: 61.88, 148.84) per 100,000 person-years, respectively (see Supplementary material 3). This suggests that by 2050, there will be 8,490,224.04 (95% CI: 5,043,207.67, 11,937,240.41) new gout cases among individuals aged 65 and older. The total number of gout patients in this age group will reach 58,686,803.59 (95% CI: 34,929,674.77, 82,443,932.41), resulting in a loss of 1,703,873.011 (95% CI: 1,000,669.949, 2,407,076.073) life years (see Supplementary material 4). Furthermore, our predictive analysis across different age groups showed that the disease burden of gout exhibits a significant upward trend across all age groups. The older the age group, the more pronounced the upward trend (see Supplementary Figures 7–9).

Figure 6

Figure 6. Predictive analysis results. (A) Age-standardized incidence rate; (B) age-standardized prevalence rate; (C) age-standardized DALYs; (D) actual values of incidence; (E) actual values of prevalence; (F) actual values of DALYs.

3.10 Risk factors for DALYs

Currently, only the risk factors contributing to gout-related DALYs have been reported. Three risk factors contribute to DALYs among gout patients: high body-mass index, kidney dysfunction, and metabolic risks. Globally, across the five SDI regions, and within the 21 GBD regions, metabolic risks are the primary risk factor for gout-related DALYs (see Figure 7A and Supplementary Figure 10). Over time, the gout disease burden attributable to various risk factors has shown an upward trend, with the increase in metabolic risks being the most prominent (see Figure 7B and Supplementary Figure 11).

Figure 7

Figure 7. Global and five SDI regions' risk factors for gout DALYs. (A) Risk factors for gout in 2021. (B) Temporal trends of gout risk factors.

4 Discussion

This study conducted a systematic analysis of the global burden and temporal trends of gout among individuals aged 65 and older from 2019 to 2021, based on data from GBD 2021. The results showed that by 2021, the age-standardized incidence rate, prevalence, and DALYs for gout in older adults had increased by 21.6%, 26.7%, and 26.4%, respectively, compared to 1990. This upward trend is consistent with the findings of Han et al. (17), who analyzed the global gout burden based on GBD 1990–2019 data. However, due to differences in the study periods and populations, the results are not directly comparable, and only a general alignment in trend can be observed.

The study further found that the burden of gout increases significantly with age. Projections indicate that by 2050, the global number of older adult individuals affected by gout will approach 58 million. It is noteworthy that the rising trend in gout burden is not solely driven by population aging; multiple factors have also played critical roles.

Studies suggest that seasonal variations may influence the frequency of gout flares through environmental temperature and humidity changes. Low temperatures in winter may promote urate crystal precipitation, while dehydration during summer may elevate serum uric acid levels, both contributing to acute attacks (18).

Our study found that the burden of gout in older adult men was significantly higher than in women, with men experiencing nearly twice the disease burden compared to women. This finding is consistent with the results of the GBD 2021 Gout Collaborators (19), and may be closely related to both physiological mechanisms and social behavior differences. First, sex-based differences in uric acid metabolism likely account for much of this disparity. A retrospective analysis indicated that men generally have higher serum uric acid levels (20). In women, estrogen exerts a protective effect by promoting uric acid excretion via the urine, thereby reducing the risk of gout (21, 22). A cross-sectional study further showed that women have an increased risk of developing gout after menopause (23), likely due to the gradual loss of estrogen-mediated protection during this period (24). Second, social behavior differences may also contribute significantly to the gout burden. Alcohol consumption is recognized as a major trigger for gout flares (25). Several studies have demonstrated that men tend to consume more alcohol than women, thereby increasing their risk of developing gout (26–28). Moreover, dietary patterns are well-established modifiable risk factors for gout. Men are more likely to consume purine-rich foods such as red meat and seafood, leading to elevated uric acid levels and an increased risk of gout (29–31). It is also worth noting that sexual orientation may indirectly influence gout risk through associated lifestyle factors. Among men who have sex with men (MSM), some studies have observed higher rates of alcohol dependence and antiretroviral therapy (e.g., protease inhibitors) use, both of which may interfere with uric acid metabolism (32). However, direct epidemiological evidence linking sexual orientation itself to gout remains limited, as existing studies primarily focus on behavioral patterns rather than sexual identity. Additionally, medication use can impact gout risk. Diuretics inhibit OAT1/OAT3-mediated uric acid secretion, cyclosporine impairs ABCG2 function, and obesity and insulin resistance exacerbate urate retention by upregulating URAT1 expression (1).

In terms of geographical distribution, gout has shown a marked upward trend in regions with a high SDI and in high-income countries. The relationship between SDI and the burden of gout is non-linear: the burden is lowest in middle-SDI regions, while it rises significantly in high-SDI countries. This may be associated with the “Westernization” of lifestyles—for example, dietary habits in high-income countries (such as high-purine and high-calorie diets) and sedentary behaviors have contributed to an increased risk of metabolic diseases such as obesity and diabetes (33, 34). In contrast, in low-SDI regions, limited access to healthcare and insufficient health management may lead to underestimation or underdiagnosis of the disease.

Additionally, we looked at the high-risk factors that contribute to gout and found that the main risk factors for gout-related DALYs were metabolic problems, kidney dysfunction, and a high body mass index. Among these, the impact of metabolic risks was particularly significant and exhibited an upward trend. This indicates that gout is not only a joint disease but also a component of metabolic syndrome. These results align with the findings of previous studies conducted by other researchers (35–37).

Predictive analysis indicates that by 2050, the incidence, prevalence, and DALYs of gout among older adults will further increase, with a significant rise in the global number of gout patients and the overall disease burden. The burden is expected to grow particularly among the oldest age groups. In response to this trend, it is imperative to implement multi-level public health strategies, including: (1) establishing early screening programs targeting high-risk older adult populations; (2) promoting community-based health management and public education to enhance awareness and self-management of gout; (3) strengthening dietary interventions and weight control at the primary care level; and (4) encouraging interdisciplinary collaboration in comprehensive prevention and management, involving fields such as nutrition, endocrinology, and geriatric medicine.

In conclusion, this study comprehensively reveals the epidemiological characteristics and trends in the burden of gout among older adults worldwide, providing valuable evidence for future disease management and health policy development. With the intensifying population aging and the prevalence of metabolic diseases, strengthening multidisciplinary collaboration and addressing gout from the perspectives of prevention, management, and policy intervention will be crucial in effectively tackling the increasingly severe burden of gout.

Data availability statement

Publicly available datasets were analyzed in this study. This data can be found here: GBD 2021, https://ghdx.healthdata.org/gbd-2021.

Ethics statement

Ethical approval was not required for the study involving humans in accordance with the local legislation and institutional requirements. Written informed consent to participate in this study was not required from the participants or the participants' legal guardians/next of kin in accordance with the national legislation and the institutional requirements.

Author contributions

XT: Funding acquisition, Writing – original draft. DD: Data curation, Writing – review & editing. QW: Data curation, Methodology, Supervision, Writing – review & editing.

Funding

The author(s) declare that no financial support was received for the research and/or publication of this article.

Acknowledgments

We thank the Institute for Health Metrics and Evaluation (IHME) for providing open access.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declare that no Gen AI was used in the creation of this manuscript.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpubh.2025.1540190/full#supplementary-material

References

1. Dalbeth N, Gosling AL, Gaffo A, Abhishek A. Gout. Lancet. (2021) 397:1843–55. doi: 10.1016/S0140-6736(21)00569-9. Erratum in: Lancet. (2021) 397:1808. doi: 10.1016/S0140-6736(21)01010-2

PubMed Abstract | Crossref Full Text | Google Scholar

2. Major TJ, Dalbeth N, Stahl EA, Merriman TR. An update on the genetics of hyperuricaemia and gout. Nat Rev Rheumatol. (2018) 14:341–53. doi: 10.1038/s41584-018-0004-x

PubMed Abstract | Crossref Full Text | Google Scholar

3. Zhong CS, Zeng B, Qiu JH, Xu LH, Zhong MY, Huang YT, et al. Gout-associated monosodium urate crystal-induced necrosis is independent of NLRP3 activity but can be suppressed by combined inhibitors for multiple signaling pathways. Acta Pharmacol Sin. (2022) 43:1324–36. doi: 10.1038/s41401-021-00749-7

PubMed Abstract | Crossref Full Text | Google Scholar

4. Dong Z, Zhou J, Jiang S, Li Y, Zhao D, Yang C, et al. Effects of multiple genetic loci on the pathogenesis from serum urate to gout. Sci Rep. (2017) 7:43614. doi: 10.1038/srep43614

PubMed Abstract | Crossref Full Text | Google Scholar

5. Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol. (2020) 16:380–90. doi: 10.1038/s41584-020-0441-1

PubMed Abstract | Crossref Full Text | Google Scholar

6. Kuo CF, Grainge MJ, Zhang W, Doherty M. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol. (2015) 11:649–62. doi: 10.1038/nrrheum.2015.91

PubMed Abstract | Crossref Full Text | Google Scholar

7. Chen-Xu M, Yokose C, Rai SK, Pillinger MH, Choi HK. Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: the National Health and Nutrition Examination Survey, 2007-2016. Arthritis Rheumatol. (2019) 71:991–9. doi: 10.1002/art.40807

PubMed Abstract | Crossref Full Text | Google Scholar

8. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. (2011) 63:3136–41. doi: 10.1002/art.30520

PubMed Abstract | Crossref Full Text | Google Scholar

9. Burke BT, Köttgen A, Law A, Grams M, Baer AN, Coresh J, et al. Gout in older adults: the Atherosclerosis Risk in Communities Study. J Gerontol A Biol Sci Med Sci. (2016) 71:536–42. doi: 10.1093/gerona/glv120

PubMed Abstract | Crossref Full Text | Google Scholar

10. Zhu B, Wang Y, Zhou W, Jin S, Shen Z, Zhang H, et al. Trend dynamics of gout prevalence among the Chinese population, 1990-2019: a joinpoint and age-period-cohort analysis. Front Public Health. (2022) 10:1008598. doi: 10.3389/fpubh.2022.1008598

PubMed Abstract | Crossref Full Text | Google Scholar

11. Singh JA, Cleveland JD. Gout and the risk of myocardial infarction in older adults: a study of Medicare recipients. Arthritis Res Ther. (2018) 20:109. doi: 10.1186/s13075-018-1606-z

PubMed Abstract | Crossref Full Text | Google Scholar

12. Safiri S, Kolahi AA, Cross M, Carson-Chahhoud K, Hoy D, Almasi-Hashiani A, et al. Prevalence, incidence, and years lived with disability due to gout and its attributable risk factors for 195 countries and territories 1990-2017: a systematic analysis of the Global Burden of Disease Study 2017. Arthritis Rheumatol. (2020) 72:1916–27. doi: 10.1002/art.41404

PubMed Abstract | Crossref Full Text | Google Scholar

13. Zhang J, Jin C, Ma B, Sun H, Chen Y, Zhong Y, et al. Global, regional and national burdens of gout in the young population from 1990 to 2019: a population-based study. RMD Open. (2023) 9:e003025. doi: 10.1136/rmdopen-2023-003025

PubMed Abstract | Crossref Full Text | Google Scholar

14. Liu K, Yao Y, Chen W, Mao Y, Ye D, Wen C. Modifiable risk factors and incidence of gout: estimation of population attributable fraction in the US. Semin Arthritis Rheum. (2022) 55:152040. doi: 10.1016/j.semarthrit.2022.152040

PubMed Abstract | Crossref Full Text | Google Scholar

15. Tang YM, Zhang L, Zhu SZ, Pan JJ, Zhou SH, He TJ, et al. Gout in China, 1990-2017: the Global Burden of Disease Study 2017. Public Health. (2021) 191:33–8. doi: 10.1016/j.puhe.2020.06.029

PubMed Abstract | Crossref Full Text | Google Scholar

16. Jin Z, Wang Z, Wang R, Xiang S, Zhang W, Tang Y, et al. Global burden and epidemic trends of gout attributable to high body mass index from 1990 to 2019. Arch Med Sci. (2024) 20:71–80. doi: 10.5114/aoms/175469

PubMed Abstract | Crossref Full Text | Google Scholar

17. Han T, Chen W, Qiu X, Wang W. Epidemiology of gout—global burden of disease research from 1990 to 2019 and future trend predictions. Ther Adv Endocrinol Metab. (2024) 15:20420188241227295. doi: 10.1177/20420188241227295

PubMed Abstract | Crossref Full Text | Google Scholar

18. Strohmaier WL, Bonkovic-Oszi J. Are there seasonal variations in renal colic in uric acid stone formers in Germany? World J Urol. (2022) 40:2099–103. doi: 10.1007/s00345-022-04058-4

PubMed Abstract | Crossref Full Text | Google Scholar

19. GBD 2021 Gout Collaborators. Global, regional, and national burden of gout, 1990-2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Rheumatol. (2024) 6:e507–17. doi: 10.1016/S2665-9913(24)00303-5

PubMed Abstract | Crossref Full Text | Google Scholar

20. Bolognesi A, Bortolotti M, Battelli MG, Polito L. Gender influence on XOR activities and related pathologies: a narrative review. Antioxidants. (2024) 13:211. doi: 10.3390/antiox13020211

PubMed Abstract | Crossref Full Text | Google Scholar

21. Halperin Kuhns VL, Woodward OM. Sex differences in urate handling. Int J Mol Sci. (2020) 21:4269. doi: 10.3390/ijms21124269

PubMed Abstract | Crossref Full Text | Google Scholar

22. Sumino H, Ichikawa S, Kanda T, Nakamura T, Sakamaki T. Reduction of serum uric acid by hormone replacement therapy in postmenopausal women with hyperuricaemia. Lancet. (1999) 354:650. doi: 10.1016/S0140-6736(99)92381-4

PubMed Abstract | Crossref Full Text | Google Scholar

23. Rodríguez-Sosa E, De Miguel E, Borrás F, Andrés M. Filling gaps in female gout: a cross-sectional study of comorbidities in 192 037 hospitalised patients. RMD Open. (2023) 9:e003191. doi: 10.1136/rmdopen-2023-003191

PubMed Abstract | Crossref Full Text | Google Scholar

24. Hak AE, Choi HK. Menopause, postmenopausal hormone use and serum uric acid levels in US women—the Third National Health and Nutrition Examination Survey. Arthritis Res Ther. (2008) 10:R116. doi: 10.1186/ar2519

PubMed Abstract | Crossref Full Text | Google Scholar

25. Gaffo AL, Roseman JM, Jacobs DR Jr, Lewis CE, Shikany JM, Mikuls TR, et al. Serum urate and its relationship with alcoholic beverage intake in men and women: findings from the Coronary Artery Risk Development in Young Adults (CARDIA) cohort. Ann Rheum Dis. (2010) 69:1965–70. doi: 10.1136/ard.2010.129429

PubMed Abstract | Crossref Full Text | Google Scholar

26. Bhole V, de Vera M, Rahman MM, Krishnan E, Choi H. Epidemiology of gout in women: fifty-two-year followup of a prospective cohort. Arthritis Rheum. (2010) 62:1069–76. doi: 10.1002/art.27338

PubMed Abstract | Crossref Full Text | Google Scholar

27. Lyu JQ, Miao MY, Wang JM, Qian YW, Han WW, Peng XZ, et al. Consumption of total and specific alcoholic beverages and long-term risk of gout among men and women. JAMA Netw Open. (2024) 7:e2430700. doi: 10.1001/jamanetworkopen.2024.30700

PubMed Abstract | Crossref Full Text | Google Scholar

28. Teramura S, Yamagishi K, Umesawa M, Hayama-Terada M, Muraki I, Maruyama K, et al. Risk factors for hyperuricemia or gout in men and women: the Circulatory Risk in Communities Study (CIRCS). J Atheroscler Thromb. (2023) 30:1483–91. doi: 10.5551/jat.63907

PubMed Abstract | Crossref Full Text | Google Scholar

29. Beydoun MA, Canas JA, Fanelli-Kuczmarski MT, Tajuddin SM, Evans MK, Zonderman AB. Genetic risk scores, sex and dietary factors interact to alter serum uric acid trajectory among African-American urban adults. Br J Nutr. (2017) 117:686–97. doi: 10.1017/S0007114517000411

PubMed Abstract | Crossref Full Text | Google Scholar

30. Su SY, Lin TH, Liu YH, Wu PY, Huang JC, Su HM, et al. Sex difference in the associations among obesity-related indices with hyperuricemia in a large Taiwanese Population Study. Nutrients. (2023) 15:3419. doi: 10.3390/nu15153419

PubMed Abstract | Crossref Full Text | Google Scholar

31. Yokose C, McCormick N, Choi HK. The role of diet in hyperuricemia and gout. Curr Opin Rheumatol. (2021) 33:135–44. doi: 10.1097/BOR.0000000000000779

PubMed Abstract | Crossref Full Text | Google Scholar

32. Guy AA, Zelaya DG, Surace A, Mastroleo NR, Pantalone DW, Monti PM, et al. Discrimination and alcohol problems among heavy drinking HIV-positive men who have sex with men: the buffering effect of a brief motivational intervention to reduce alcohol use. Drug Alcohol Depend. (2022) 233:109384. doi: 10.1016/j.drugalcdep.2022.109384

PubMed Abstract | Crossref Full Text | Google Scholar

33. McCormick N, Rai SK, Lu N, Yokose C, Curhan GC, Choi HK. Estimation of primary prevention of gout in men through modification of obesity and other key lifestyle factors. JAMA Netw Open. (2020) 3:e2027421. doi: 10.1001/jamanetworkopen.2020.27421

PubMed Abstract | Crossref Full Text | Google Scholar

34. Sun S, Chen L, Chen D, Li Y, Liu G, Ma L, et al. Prevalence and associated factors of hyperuricemia among Chinese patients with diabetes: a cross-sectional study. Ther Adv Endocrinol Metab. (2023) 14:20420188231198620. doi: 10.1177/20420188231198620

PubMed Abstract | Crossref Full Text | Google Scholar

35. Tu YC, Liu YH, Chen SC, Su HM. Metabolic syndrome and its components are associated with new-onset hyperuricemia in a large Taiwanese population follow-up study. Nutrients. (2023) 15:1083. doi: 10.3390/nu15051083

PubMed Abstract | Crossref Full Text | Google Scholar

36. Yao S, Zhou Y, Xu L, Zhang Q, Bao S, Feng H, et al. Association between hyperuricemia and metabolic syndrome: a cross-sectional study in Tibetan adults on the Tibetan plateau. Front Endocrinol. (2022) 13:964872. doi: 10.3389/fendo.2022.964872

PubMed Abstract | Crossref Full Text | Google Scholar

37. Huang G, Xu J, Zhang T, Cai L, Liu H, Yu X, et al. Hyperuricemia is associated with metabolic syndrome in the community very elderly in Chengdu. Sci Rep. (2020) 10:8678. doi: 10.1038/s41598-020-65605-w

PubMed Abstract | Crossref Full Text | Google Scholar

38. Murray CJL, GBD 2021 Collaborators. Findings from the Global Burden of Disease Study 2021. Lancet. (2024) 403:2259–62. doi: 10.1016/S0140-6736(24)00769-4

PubMed Abstract | Crossref Full Text | Google Scholar

39. GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. (2023) 402:203–34. doi: 10.1016/S0140-6736(23)01301-6. Erratum in: Lancet. (2023) 402:1132. Erratum in: Lancet. (2025) 405:202. doi: 10.1016/S0140-6736(25)00053-4

PubMed Abstract | Crossref Full Text | Google Scholar

40. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. (2020) 396:1204–1222. doi: 10.1016/S0140-6736(20)30925-9. Erratum in: Lancet. (2020) 396:1562. doi: 10.1016/S0140-6736(20)32226-1

PubMed Abstract | Crossref Full Text | Google Scholar

41. Liu Z, Jiang Y, Yuan H, Fang Q, Cai N, Suo C, et al. The trends in incidence of primary liver cancer caused by specific etiologies: Results from the Global Burden of Disease Study 2016 and implications for liver cancer prevention. J Hepatol. (2019) 70:674–83. doi: 10.1016/j.jhep.2018.12.001

PubMed Abstract | Crossref Full Text | Google Scholar

42. Cao F, Liu YC, Ni QY, Chen Y, Wan CH, Liu SY, et al. Temporal trends in the prevalence of autoimmune diseases from 1990 to 2019. Autoimmun Rev. (2023) 22:103359. doi: 10.1016/j.autrev.2023.103359

PubMed Abstract | Crossref Full Text | Google Scholar

43. Global Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol. (2017) 3:524–548. doi: 10.1001/jamaoncol.2016.5688. Erratum in: JAMA Oncol. (2017) 3:418. doi: 10.1001/jamaoncol.2017.0098

PubMed Abstract | Crossref Full Text | Google Scholar

44. Luo L. Assessing validity and application scope of the intrinsic estimator approach to the age-period-cohort problem. Demography. (2013) 50:1945–67. doi: 10.1007/s13524-013-0243-z

PubMed Abstract | Crossref Full Text | Google Scholar

45. Hu W, Fang L, Zhang H, Ni R, Pan G. Global disease burden of COPD from 1990 to 2019 and prediction of future disease burden trend in China. Public Health. (2022) 208:89–97. doi: 10.1016/j.puhe.2022.04.015

PubMed Abstract | Crossref Full Text | Google Scholar